P115 (0048) BRENTUXIMAB VEDOTIN (BV) AS MAINTENANCE OR SALVAGE THERAPY AFTER ASCT FOR RELAPSED/REFRACTORY (R/R) HL

P115 (0048) BRENTUXIMAB VEDOTIN (BV) AS MAINTENANCE OR SALVAGE THERAPY AFTER ASCT FOR RELAPSED/REFRACTORY (R/R) HL

Bibliographic Details
Format:	Article
Language:	English
Published:	Wiley 2018-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000547960.36500.e8

Similar Items

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
by: Feng-Ming Tien, et al.
Published: (2019-10-01)

P119 (0078) REAL LIFE DATA OF BRENTUXIMAB VEDOTIN USE IN RELAPSED/REFRACTORY HL IN SWEDEN
Published: (2018-10-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

P120 (0086) OUTCOMES AND TOXICITIES AFTER BRENTUXIMAB VEDOTIN (BV) MAINTENANCE IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENT EXPOSED TO BV PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT
Published: (2018-10-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

P135 (0160) BRENTUXIMAB-VEDOTIN + BENDAMUSTINE: A HIGHLY EFFECTIVE SALVAGE TREATMENT UN REFRACTORY/RELAPSED PATIENTS WITH HODGKIN LYMPHOMA
Published: (2018-10-01)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
by: Swetha Kambhampati, et al.
Published: (2022-10-01)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
by: Matthew Mei, et al.
Published: (2022-10-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
by: Sophie Voruz, et al.
Published: (2021-05-01)

Brentuximab vedotin induced uveitis
by: Stijn Therssen, M.D., et al.
Published: (2022-06-01)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
by: Fulvio Massaro, et al.
Published: (2022-02-01)

P139 (0169) BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY FOR PRIMARY REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MULTICENTRE EXPERIENCE OF THE POLISH LYMPHOMA RESEARCH GROUP
Published: (2018-10-01)

P017 (0120) IMMUNOLOGIC BIOMARKERS OF RESPONSE AND RESISTANCE TO BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
by: Sharon M. Castellino, et al.
Published: (2022-10-01)

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
by: Chen R, et al.
Published: (2015-04-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
by: Jozef Michalka, et al.
Published: (2022-10-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
by: Cesar Gentille, et al.
Published: (2022-07-01)

P121 (0089) SEQUENTIAL TIME-INTENSIFIED BRENTUXIMAB VEDOTIN (BV) FOLLOWED BY GEMCITABINE, VINORELBINE AND PEGYLATED LIPOSOMAL DOXORUBICINE (GVD) AS A BRIDGE TO AUTOLOGOUS TRANSPLANTATION IN DHAP RESISTANT RELAPSED OR REFRACTORY CD30+ LYMPHOMA
Published: (2018-10-01)

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
by: Shelagh M Szabo, et al.
Published: (2017-01-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Real experience of brentuximab vedotin for cutaneous T cell lymphomas
by: F. Keklik Karadag, et al.
Published: (2020-10-01)

Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy
by: Francesca Fiorentino, et al.
Published: (2023-01-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
by: Eyre, T, et al.
Published: (2017)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
by: Susan Y. Wu, MD, et al.
Published: (2023-11-01)

Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy
by: Francesca Fiorentino, et al.
Published: (2023-10-01)

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
by: Federica Giannotti, et al.
Published: (2024-03-01)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
by: Anna Sureda-Balari, et al.
Published: (2022-10-01)

P110 (0014) SUCCESSFUL TREATMENT OF HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Published: (2018-10-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report
by: Attilio Di Girolamo, et al.
Published: (2018-10-01)